We are pleased to announce that our group company Constance Therapeutics (CT) has been awarded its third patent by U.S. Patent and Trademark Office.
The patent has been issued as U.S. Pat. No. 10,806,707, titled “Cannabis Oil Compositions and Methods for Preparations Thereof.”
Claims in the patent are directed to CT’s combinations of cannabinoids and essential oils in the form of gel capsules for oral and pulmonary administration, as well as to a method for treating Lyme disease using the gel capsules. The patent is part of CT’s larger patent portfolio, claiming priority to filings in 2015, with applications pending in the United States, Canada, Israel, the European Patent Office, Australia, Colombia and Mexico. As such, the company’s suite of proprietary cannabis compositions and the underlying methodologies to produce them are patent pending on a global basis.
CT’s technology is based on years’ worth of research and development by the company and its founder, Constance Finley. Finley’s first experiences in cannabis extraction were with “out of options” patients with serious medical conditions such as Stage IV cancer and chronic auto immune conditions including Lyme disease, rheumatoid arthritis and MS. Her innovations originated in the early days of California medicinal cannabis, when the only delivery options were problematic for many and ineffective for the most serous conditions. The need for effective and non-toxic delivery methods and formulations of medicinal cannabis products set Finley on a path of research and discovery resulting in the founding of Constance Therapeutics.
Constance Finley, Constance Therapeutics